Shares in Novo Nordisk fell as much as 30% after it slashed sales and profits forecasts for the second time this year amid ...

(Reuters) -Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than Danish rival Novo Nordisk did on Tuesday, and are anxiously awaiting a ...

* Researchers at the Danish Headache Center are testing semaglutide along with a very low calorie diet as a treatment for new ...

Eli Lilly is expected to report robust quarterly sales and profits, outpacing its Danish rival Novo Nordisk. Despite some ...

Eli Lilly stock slips after Novo Nordisk trims 2025 forecast; Jaypirca meets endpoint in CLL trial against J&J's Imbruvica, ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin drug strategy.

LLY has slid 15.7% over the past year, but surging demand for Mounjaro and Zepbound could revive the stock's momentum.

LLY's $1.3 billion Verve deal marks its third M&A in 2025 as it pushes to diversify across cardiovascular, neuro and cancer therapies.

An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March 28, 2024.

Eli Lilly (NYSE: LLY) sells a broad range of medicines, from cancer and immunology drugs to treatments for migraine. The pharma giant's presence across several treatment areas has helped it grow ...

Eli Lilly is worth a premium considering the strength of its financial results, even if the stock is somewhat volatile in the short term. The company's work in weight management, diabetes, and ...

Meanwhile, Lilly is notching win after win. Eli Lilly's position in the weight management market makes its stock attractive, considering how fast this area is projected to grow in the coming years. 2.